

ARUP Test Code: 3001541  
Collection Date: 11/12/2023  
Received in lab: 11/12/2023  
Completion Date: 11/17/2023

## WARF PAN Whole Blood

### Patient Results

Gene	Genotype	Flag	Phenotype	Flag
CYP2C9	*1/*3		Intermediate	A
CYP2C Cluster	Heterozygous	A	See Note	A
CYP4F2	*1/*3	A	See Note	
VKORC1	*1/*2	A	See Note	A

### WARF PAN Interpretation

See Note


The following CYP2C9 allele(s) were detected: \*1/\*3. This result predicts the intermediate metabolizer phenotype, with an activity score of 1 of 2.

One copy of the 2C cluster rs12777823 was detected. This variant is associated with reduced warfarin dose requirement in some individuals of African ancestry.

CYP4F2 is associated with vitamin K recycling. Presence of the \*3 allele could be associated with a modest increased warfarin dose requirement in some populations, such as Whites and Asians, but not in other populations such as African Americans or Egyptians.

VKORC1 is the therapeutic target for warfarin. The \*2 allele is associated with decreased gene expression and increased warfarin sensitivity (reduced dose requirement). The effect on warfarin sensitivity and dose requirement is more significant for homozygotes than for heterozygotes.

Gene-based dosing calculators such as [www.WarfarinDosing.org](http://www.WarfarinDosing.org) are available. Guidelines for genotype-based dosing are published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and can be found at: <https://cpicpgx.org/> and <https://www.pharmgkb.org/>.

This result has been reviewed and approved by 

### Interpretive Comments



## BACKGROUND INFORMATION: Warfarin Sensitivity (CYP2C9, CYP2C cluster, CYP4F2, VKORC1) Genotyping

Characteristics: Warfarin sensitivity can lead to a life-threatening overdose event such as excessive bleeding. Genetic variation is recognized to explain a large proportion of variability in warfarin dose requirements. This test may predict individual warfarin sensitivity and non-standard dose requirements. The cytochrome P450 (CYP) isozyme 2C9 is involved in the metabolism of many drugs. Variants in the gene that codes CYP2C9 may influence pharmacokinetics of substrates such as warfarin, and may predict or explain non-standard dose requirements, therapeutic failure or adverse reactions. Variants in the VKORC1 and CYP4F2 genes may predict sensitivity to warfarin. The CYP2C cluster variant, rs12777823, common in people of African descent, with a minor allele frequency of approximately 25 percent, is found to be associated with warfarin dose in this population. Genetic information and non-genetic factors can be used in combination with warfarin dose calculators, such as through [www.WarfarinDosing.org](http://www.WarfarinDosing.org). Inheritance: Autosomal codominant.

Cause: CYP2C9 and CYP2C cluster variants are associated with reduced dose requirements. The VKORC1\*2 allele is associated with reduced expression of the warfarin target, vitamin K epoxide reductase (VKOR), and a reduced dose requirement. The CYP4F2 variant is associated with an increased dose requirement.

### Variants Tested:

(Variants are numbered according to the following transcripts: CYP2C9 NM\_000771, 2C cluster rs12777823, CYP4F2 NM\_001082 and VKORC1 NM\_024006).

\*1: Indicative of no detected targeted variants and an assumption of functional allele.

CYP2C9\*2: rs1799853, c.430C>T  
CYP2C9\*3: rs1057910, c.1075A>C  
CYP2C9\*4: rs56165452, c.1076T>C  
CYP2C9\*5: rs28371686, c.1080C>G  
CYP2C9\*6: rs9332131, c.818del  
CYP2C9\*8: rs7900194, c.449G>A  
CYP2C9\*11: rs28371685, c.1003C>T  
CYP2C9\*12: rs9332239, c.1465C>T

CYP2C rs12777823, g.96405502 G>A

CYP4F2\*3: rs2108622, c.1297g>a

VKORC1\*2: rs9923231, c.-1639G>A

Clinical Sensitivity: Genetic factors and known non-genetic factors account for approximately 50 percent of the variability in warfarin dose.

Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring.

Analytical Sensitivity and Specificity: Greater than 99 percent.

Limitations: Only the targeted CYP2C9, CYP2C cluster, CYP4F2 and



[REDACTED]

VKORC1 variants will be detected by this panel, and assumptions about phase and content are made to assign alleles. Publicly available sources such as the [www.pharmvar.org](http://www.pharmvar.org) or [www.pharmgkb.org](http://www.pharmgkb.org) provide guidance on phenotype predictions and allele frequencies. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with CYP2C9 substrates may be affected by genetic and non-genetic factors that are not detected by this test. This result does not replace the need for therapeutic drug or clinical monitoring.

Please note the information contained in this report does not contain medication recommendations, and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.



**Test Information**

The following tables list the available gene-drug pairs and genotype-based dosing published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the FDA table of pharmacogenomic biomarkers in drug labeling.

**Published CPIC guidelines**

<b>GUIDELINES</b>	<b>DRUGS</b>	<b>GENES</b>
CYP2B6 and efavirenz	efavirenz	CYP2B6
CYP2C19 and Clopidogrel	clopidogrel	CYP2C19
CYP2C19 and Proton Pump Inhibitors	dexlansoprazole	CYP2C19
	esomeprazole	
	lansoprazole	
	omeprazole	
	pantoprazole	
	rabeprazole	
CYP2C19 and Voriconazole	voriconazole	CYP2C19
CYP2C9 and NSAIDs	aceclofenac	CYP2C9
	celecoxib	
	diclofenac	
	flurbiprofen	
	ibuprofen	
	indomethacin	
	lornoxicam	
	lumiracoxib	
	meloxicam	
	metamizole	
	nabumetone	
	naproxen	
	piroxicam	
tenoxicam		
CYP2C9, VKORC1, CYP4F2 and Warfarin	warfarin	CYP2C9, CYP4F2, VKORC1
CYP2D6 and Atomoxetine	atomoxetine	CYP2D6
CYP2D6 and Ondansetron and Tropisetron	ondansetron	CYP2D6
	tropisetron	
CYP2D6 and Tamoxifen	tamoxifen	CYP2D6
	citalopram	
	escitalopram	



# Warfarin Sensitivity (CYP2C9, CYP2C cluster, CYP4F2, VKORC1) Genotyping

CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors	fluvoxamine	CYP2C19, CYP2D6
	paroxetine	
	sertraline	
CYP2D6, CYP2C19 and Tricyclic Antidepressants	amitriptyline	CYP2C19, CYP2D6
	clomipramine	
	desipramine	
	doxepin	
	imipramine	
	nortriptyline	
	trimipramine	
CYP2D6, OPRM1, COMT, and Opioids	alfentanil	COMT, CYP2D6, OPRM1
	buprenorphine	
	codeine	
	fentanyl	
	hydrocodone	
	hydromorphone	
	levomethadone	
	methadone	
	morphine	
	naltrexone	
	oxycodone	
	remifentanil	
	sufentanil	
	tramadol	
CYP3A5 and Tacrolimus	tacrolimus	CYP3A5
DPYD and Fluoropyrimidines	capecitabine	DPYD
	fluorouracil	
	tegafur	
SLCO1B1, ABCG2, CYP2C9, and Statins	atorvastatin	ABCG2, CYP2C9, SLCO1B1
	fluvastatin	
	lovastatin	
	pitavastatin	
	pravastatin	
	rosuvastatin	
	simvastatin	
	azathioprine	





TPMT, NUDT15 and Thiopurines

mercaptopurine

NUDT15, TPMT

thioguanine



**FDA Table of Pharmacogenomic Biomarkers in Drug Labeling**

Drug	Therapeutic Area*	Biomarker†	Labeling Sections
Abrocitinib	Dermatology	CYP2C19	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Amitriptyline	Psychiatry	CYP2D6	Precautions
Amoxapine	Psychiatry	CYP2D6	Precautions
Amphetamine	Psychiatry	CYP2D6	Clinical Pharmacology
Arformoterol	Pulmonary	CYP2D6	Clinical Pharmacology
Aripiprazole	Psychiatry	CYP2D6	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Aripiprazole Lauroxil	Psychiatry	CYP2D6	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Atomoxetine	Psychiatry	CYP2D6	Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology
Avatrombopag	Hematology	CYP2C9	Clinical Pharmacology
Azathioprine	Rheumatology	TPMT	Dosage and Administration, Warnings, Precautions, Drug Interactions, Adverse Reactions, Clinical Pharmacology
Azathioprine	Rheumatology	NUDT15	Dosage and Administration, Warnings, Precautions, Adverse Reactions, Clinical Pharmacology
Belzutifan	Oncology	CYP2C19	Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology
Brexpiprazole	Psychiatry	CYP2D6	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Brivaracetam	Neurology	CYP2C19	Clinical Pharmacology
Bupropion	Psychiatry	CYP2D6	Clinical Pharmacology
Capecitabine	Oncology	DPYD	Warnings and Precautions, Clinical Pharmacology, Patient Counseling Information
Cariprazine	Psychiatry	CYP2D6	Clinical Pharmacology
Carisoprodol	Rheumatology	CYP2C19	Use in Specific Populations, Clinical Pharmacology
Carvedilol	Cardiology	CYP2D6	Drug Interactions, Clinical Pharmacology
Celecoxib	Rheumatology	CYP2C9	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Cevimeline	Dental	CYP2D6	Precautions
Cisplatin	Oncology	TPMT	Adverse Reactions
Citalopram	Psychiatry	CYP2C19	Dosage and Administration, Warnings, Clinical Pharmacology



# Warfarin Sensitivity (CYP2C9, CYP2C cluster, CYP4F2, VKORC1) Genotyping

Citalopram	Psychiatry	CYP2D6	Clinical Pharmacology
Clobazam	Neurology	CYP2C19	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Clomipramine	Psychiatry	CYP2D6	Precautions
Clopidogrel	Cardiology	CYP2C19	Boxed Warning, Warnings and Precautions, Clinical Pharmacology
Clozapine	Psychiatry	CYP2D6	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Codeine	Anesthesiology	CYP2D6	Boxed Warning, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information
Darifenacin	Urology	CYP2D6	Clinical Pharmacology
Desipramine	Psychiatry	CYP2D6	Precautions
Desvenlafaxine	Psychiatry	CYP2D6	Clinical Pharmacology
Deutetrabenazine	Neurology	CYP2D6	Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology
Dexlansoprazole	Gastroenterology	CYP2C19	Drug Interactions, Clinical Pharmacology
Dextromethorphan and Quinidine	Neurology	CYP2D6	Warnings and Precautions, Clinical Pharmacology
Diazepam	Neurology	CYP2C19	Clinical Pharmacology
Donepezil	Neurology	CYP2D6	Clinical Pharmacology
Doxepin	Psychiatry	CYP2D6	Clinical Pharmacology
Doxepin	Psychiatry	CYP2C19	Clinical Pharmacology
Dronabinol	Gastroenterology	CYP2C9	Use in Specific Populations, Clinical Pharmacology
Drospirenone and Ethinyl Estradiol	Gynecology	CYP2C19	Clinical Pharmacology
Duloxetine	Psychiatry	CYP2D6	Drug Interactions
Efavirenz	Infectious Diseases	CYP2B6	Clinical Pharmacology
Elagolix	Gynecology	SLCO1B1	Clinical Pharmacology
Eliglustat	Inborn Errors of Metabolism	CYP2D6	Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies
Erdafitinib	Oncology	CYP2C9	Use in Specific Populations, Clinical Pharmacology
Escitalopram	Psychiatry	CYP2D6	Drug Interactions
Escitalopram	Psychiatry	CYP2C19	Adverse Reactions
Esomeprazole	Gastroenterology	CYP2C19	Drug Interactions, Clinical Pharmacology





# Warfarin Sensitivity (CYP2C9, CYP2C cluster, CYP4F2, VKORC1) Genotyping

Fesoterodine	Urology	CYP2D6	Drug Interactions, Clinical Pharmacology
Fosphenytoin	Neurology	CYP2C9	Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology
Flibanserin	Gynecology	CYP2C9	Clinical Pharmacology
Flibanserin	Gynecology	CYP2C19	Adverse Reactions, Use in Specific Populations, Clinical Pharmacology
Flibanserin	Gynecology	CYP2D6	Clinical Pharmacology
Fluorouracil	Dermatology	DPYD	Contraindications, Warnings
Fluorouracil	Oncology	DPYD	Warnings and Precautions, Patient Counseling Information
Fluoxetine	Psychiatry	CYP2D6	Precautions, Clinical Pharmacology
Flurbiprofen	Rheumatology	CYP2C9	Clinical Pharmacology
Fluvoxamine	Psychiatry	CYP2D6	Drug Interactions
Formoterol	Pulmonary	CYP2D6	Clinical Pharmacology
Formoterol	Pulmonary	CYP2C19	Clinical Pharmacology
Galantamine	Neurology	CYP2D6	Clinical Pharmacology
Gefitinib	Oncology	CYP2D6	Clinical Pharmacology
lloperidone	Psychiatry	CYP2D6	Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology
Imipramine	Psychiatry	CYP2D6	Precautions
Lacosamide	Neurology	CYP2C19	Clinical Pharmacology
Lansoprazole	Gastroenterology	CYP2C19	Drug Interactions, Clinical Pharmacology
Lesinurad	Rheumatology	CYP2C9	Drug Interactions, Clinical Pharmacology
Lofexidine	Anesthesiology	CYP2D6	Use in Specific Populations
Mavacamten	Cardiology	CYP2C19	Dosage and Administration, Clinical Pharmacology
Meclizine	Neurology	CYP2D6	Warnings and Precautions
Meloxicam	Anesthesiology	CYP2C9	Use in Specific Populations, Clinical Pharmacology
Mercaptopurine	Oncology	TPMT	Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology
Mercaptopurine	Oncology	NUDT15	Dosage and Administration, Warnings and Precautions, Clinical Pharmacology
Metoclopramide	Gastroenterology	CYP2D6	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Metoprolol	Cardiology	CYP2D6	Clinical Pharmacology
Mirabegron	Urology	CYP2D6	Clinical Pharmacology
Modafinil	Psychiatry	CYP2D6	Clinical Pharmacology



# Warfarin Sensitivity (CYP2C9, CYP2C cluster, CYP4F2, VKORC1) Genotyping

Nateglinide	Endocrinology	CYP2C9	Drug Interactions
Nebivolol	Cardiology	CYP2D6	Dosage and Administration, Clinical Pharmacology
Nefazodone	Psychiatry	CYP2D6	Precautions
Nortriptyline	Psychiatry	CYP2D6	Precautions
Oliceridine	Anesthesiology	CYP2D6	Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology
Omeprazole	Gastroenterology	CYP2C19	Drug Interactions, Clinical Pharmacology
Ondansetron	Gastroenterology	CYP2D6	Clinical Pharmacology
Ospemifene	Gynecology	CYP2C9	Clinical Pharmacology
Ospemifene	Gynecology	CYP2B6	Clinical Pharmacology
Paliperidone	Psychiatry	CYP2D6	Clinical Pharmacology
Palonosetron	Gastroenterology	CYP2D6	Clinical Pharmacology
Pantoprazole	Gastroenterology	CYP2C19	Clinical Pharmacology
Paroxetine	Psychiatry	CYP2D6	Drug Interactions, Clinical Pharmacology
Perphenazine	Psychiatry	CYP2D6	Precautions, Clinical Pharmacology
Phenytoin	Neurology	CYP2C9	Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology
Phenytoin	Neurology	CYP2C19	Clinical Pharmacology
Pimozide	Psychiatry	CYP2D6	Dosage and Administration, Precautions
Piroxicam	Rheumatology	CYP2C9	Clinical Pharmacology
Pitolisant	Psychiatry	CYP2D6	Dosage and Administration, Use in Specific Populations, Clinical Pharmacology
Prasugrel	Cardiology	CYP2C19	Use in Specific Populations, Clinical Pharmacology, Clinical Studies
Prasugrel	Cardiology	CYP2C9	Use in Specific Populations, Clinical Pharmacology, Clinical Studies
Prasugrel	Cardiology	CYP3A5	Use in Specific Populations, Clinical Pharmacology, Clinical Studies
Prasugrel	Cardiology	CYP2B6	Use in Specific Populations, Clinical Pharmacology, Clinical Studies
Propafenone	Cardiology	CYP2D6	Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology
Propranolol	Cardiology	CYP2D6	Clinical Pharmacology
Protriptyline	Psychiatry	CYP2D6	Precautions
Quinidine	Cardiology	CYP2D6	Precautions
Quinine Sulfate	Infectious Diseases	CYP2D6	Drug Interactions



# Warfarin Sensitivity (CYP2C9, CYP2C cluster, CYP4F2, VKORC1) Genotyping

Rabeprazole	Gastroenterology	CYP2C19	Drug Interactions, Clinical Pharmacology
Rimegepant	Neurology	CYP2C9	Clinical Pharmacology
Risperidone	Psychiatry	CYP2D6	Clinical Pharmacology
Rosuvastatin	Endocrinology	SLCO1B1	Clinical Pharmacology
Rucaparib (2)	Oncology	CYP2D6	Clinical Pharmacology
Siponimod	Neurology	CYP2C9	Dosage and Administration, Contraindications, Drug Interactions, Use in Specific Populations, Clinical Pharmacology
Tamoxifen	Oncology	CYP2D6	Clinical Pharmacology
Tamsulosin	Urology	CYP2D6	Warnings and Precautions, Adverse Interactions, Clinical Pharmacology
Tetrabenazine	Neurology	CYP2D6	Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology
Thioguanine	Oncology	TPMT	Dosage and Administration, Warnings, Precautions, Clinical Pharmacology
Thioguanine	Oncology	NUDT15	Dosage and Administration, Warnings, Precautions, Clinical Pharmacology
Thioridazine	Psychiatry	CYP2D6	Contraindications, Warnings, Precautions
Ticagrelor	Cardiology	CYP2C19	Clinical Pharmacology
Tolterodine	Urology	CYP2D6	Warnings and Precautions, Drug Interactions, Clinical Pharmacology
Tramadol	Anesthesiology	CYP2D6	Boxed Warning, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Patient Counseling Information
Trimipramine	Psychiatry	CYP2D6	Precautions
Umeclidinium	Pulmonary	CYP2D6	Clinical Pharmacology
Upadacitinib	Rheumatology	CYP2D6	Clinical Pharmacology
Valbenazine	Neurology	CYP2D6	Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology
Venlafaxine	Psychiatry	CYP2D6	Drug Interactions, Use in Specific Populations, Clinical Pharmacology
Viloxazine	Psychiatry	CYP2D6	Clinical Pharmacology
Viloxazine	Psychiatry	SLCO1B1	Clinical Pharmacology
Voriconazole	Infectious Diseases	CYP2C19	Clinical Pharmacology
Vortioxetine	Psychiatry	CYP2D6	Dosage and Administration, Clinical Pharmacology
Warfarin	Hematology	CYP2C9	Dosage and Administration, Drug Interactions, Clinical Pharmacology



# Warfarin Sensitivity (CYP2C9, CYP2C cluster, CYP4F2, VKORC1) Genotyping



Warfarin	Hematology	VKORC1	Dosage and Administration, Clinical Pharmacology
----------	------------	--------	--------------------------------------------------

\* Therapeutic areas do not necessarily reflect the CDER review division.

† Representative biomarkers are listed based on standard nomenclature as per the Human Genome Organization (HUGO) symbol and/or simplified descriptors using other common conventions. Listed biomarkers do not necessarily reflect the terminology used in labeling. The term "Nonspecific" is provided when labeling does not explicitly identify the specific biomarker(s) or when the biomarker is represented by a molecular phenotype or gene signature, and in some cases the biomarker was inferred based on the labeling language.

